Related Experiment Video
Updated: Feb 4, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
Miso Kim1, Tae Min Kim2, Bhumsuk Keam1
1Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Lessons Learned:
Pazopanib shows a modest efficacy in metastatic alveolar soft part sarcoma.Clinical outcomes were comparable to those in previous studies using antiangiogenic drugs.Further prospective studies evaluating the benefit of pazopanib in alveolar soft part sarcoma with a larger sample are warranted to validate results.
Background:
Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignant tumor characterized by an unbalanced translocation, t(X;17)(p11.2;q25), which leads to the fusion of ASPSCR1 to the TFE3 transcription factor. Because this results in the upregulation of angiogenesis-related transcripts, antiangiogenic drugs have been used in ASPS patients.
Methods:
This open-label, single-arm, multicenter, investigator-initiated phase II trial was designed to evaluate efficacy and safety of pazopanib 800 mg once daily in patients with metastatic ASPS. The primary endpoint was investigator-assessed overall response rate (ORR), and secondary endpoints were toxicity, progression-free survival (PFS), and overall survival (OS). 68Ga-RGD (Arg-Gly-Asp) positron emission tomography (PET) scan and gene expression profiling using NanoString platform were performed for biomarker analysis.
Results:
Six patients with histologically confirmed metastatic ASPS were enrolled between December 2013 and November 2014. Among six patients, one achieved a partial response (PR) (ORR 16.7%) and five patients showed stable disease (SD). With a median follow-up of 33 months (range 18.7-39.3 months), median PFS was 5.5 months (95% confidence interval [CI] 3.4-7.6 months), and median OS was not reached. There were no severe toxicities except one patient with grade 3 diarrhea.
Conclusion:
Pazopanib showed modest antitumor activity with manageable toxicities for patients with metastatic ASPS.
Insights
Pazopanib demonstrated modest efficacy in treating metastatic alveolar soft part sarcoma (ASPS). This antiangiogenic drug showed manageable toxicity, supporting further investigation in larger clinical trials for ASPS patients.
Area of Science:
- Oncology
- Medical Science
- Pharmacology
Background:
- Alveolar soft part sarcoma (ASPS) is a rare malignancy driven by a specific genetic translocation (t(X;17)(p11.2;q25)) leading to angiogenesis.
- Antiangiogenic therapies are a therapeutic strategy for ASPS due to the upregulation of angiogenesis-related genes.
Purpose of the Study:
- To evaluate the efficacy and safety of pazopanib in patients with metastatic ASPS.
- To assess overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) as primary and secondary endpoints.
Main Methods:
- An open-label, single-arm, multicenter Phase II clinical trial.
- Pazopanib 800 mg administered once daily to patients with metastatic ASPS.
- Biomarker analysis included 68Ga-RGD PET scans and NanoString gene expression profiling.
Main Results:
- One partial response (16.7% ORR) and stable disease in five patients.
- Median PFS was 5.5 months; median OS was not reached.
- The treatment was generally well-tolerated, with one case of grade 3 diarrhea being the most significant toxicity.
Conclusions:
- Pazopanib exhibits modest antitumor activity in metastatic ASPS.
- The drug presents a manageable toxicity profile for ASPS patients.
- Further prospective studies with larger cohorts are needed to confirm pazopanib's benefit in ASPS.
Related Concept Videos
Alveoli and Alveolar Ducts
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Phase Diagrams
Phase Transitions

